Chronic Kidney Disease
Similar results in measuring time to kidney failure for kidney failure risk equation, eGFR
Measuring time to kidney failure in advanced chronic kidney disease can inform clinical decisions and patient counseling, regardless of estimates based on eGFR or the kidney failure risk equation, according to recently published data.
Meta-analysis confirms benefits of SGLT2 inhibitors in various high-risk populations
SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology.
Ace the Case: A 22-Year-Old Man With Hematuria
There is no commercial support for this activity.
IV iron therapy may not improve exercise ability in patients with CKD
Intravenous iron therapy did not improve exercise capacity in nonanemic patients with iron deficiency who have chronic kidney disease, according to recently published data.
Treating high BP can reduce the risks of ESKD, but measuring it correctly is key
“The most important skill you will learn in your medical career is to measure blood pressure. Do it correctly and you will help more patients to better health than with any other skill you learn. Do it wrong and you will harm more patients than with any other medical errors you make over your career.” — Clarence E. Grim, MD
Healio celebrates National Nurses Month
With May serving as National Nurses Month, Healio has collected the top stories in nephrology that discuss the challenges faced by nurses who treat patients with kidney disease.
Empagliflozin HF benefits extend across spectrum of kidney disease
Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study.
High post-dexamethasone cortisol levels linked to lower eGFR independent of CV factors
SEATTLE — Higher post-dexamethasone cortisol was associated with lower estimated glomerular filtration rate independent of cardiovascular risk factors, researchers reported at the AACE Annual Scientific and Clinical Conference.
Gene testing more beneficial than clinical review in identifying Townes-Brocks Syndrome
AUSTIN, Texas — A broad kidney gene panel will frequently help diagnosis renal syndromes more effectively than classical clinical review alone, researchers reported here.
FDA grants fast-track designation to potential CD19-CAR T cell therapy for lupus
The FDA has granted fast-track designation to CABA-201, a CD19-CAR T cell investigational therapy, for the treatment of systemic lupus erythematous and lupus nephritis, according to a press release from the manufacturer.